

Supplementary Data

Reticular Pseudodrusen Consortium members

Principal Investigators: Robyn H Guymer, Alice Pébay, Erica L Fletcher, Melanie Bahlo, Brendan RE Ansell and Zhichao Wu

Project manager: Carla J Abbott

Genetic cohorts: Elvira Agron, Lebriz Altay, Ella Arnon, Louis Arnould, Mary Attia, Bjorn Bakker, Konstantinos Balaskas, Melinda Cain, Emily Caruso, Usha Chakravarthy, Jason Charng, Attiqa Chaudhary, Fred K Chen, Shang-Chih Chen, Emily Chew, Sae Cho, Itay Chowers, Linda Clarke, Audrey Cougnard-Grégoire, Catherine Creuzot Garcher, Catherine Cukras, Stéphanie Debette, Cécile Delcourt, Marie-Noëlle Delyfer, Anneke I den Hollander, Layal El Wazan, Sarah Elbaz-Hayun, Sascha Fauser, Daniela Ferrara, Robert P Finger, Pierre-Henry Gabrielle, Javier Gayan, Erin Gee, Emily Glover, Kai Lyn Goh, Michelle Grunin, Rachael Heath Jeffery, Catherine Helmer, Wilson Heriot, Claire Hill, Lauren AB Hodgson, Ruth Hogg, Frank G Holz, Carel Hoyng, Amy Kalantary, Haya Kashtan, Pearse A Keane, Frank Kee, Tiarnan Keenan, Samer Khateb, Meme Ko, Jean-François Korobelnik, Adi Kremer, Himeesh Kumar, Eleonora M Lad, Mélanie Le Goff, Yara Lechanteur, Jackson Lee, Rivkah Lender, Jaime Levi, Sandra Liakopoulos, Timing Liu, Ulrich FO Luhmann, Chi D Luu, Matthias M Mauschitz, Amy J McKnight, Samuel McLenachan, Aniket Mishra, Ismail Moghul, Tunde Peto, Nikolas Pontikos, Anna Rautanen, Batya Rinsky, Danial Roshandel, Danuta M Sampson, Sean Santiago, Tina Schick, Cédric Schweitzer, Merav Shiryon, Michal Shpigel, Yahel Shwartz, Vasilena Sitnilska, Laura Smyth, Amy Stockwell, Jan H Terheyden, Nikita Thomas, Liran Tiosano, Adnan Tufail, Claire Weber, Brian L Yaspan, MACUSTAR Consortium, NICOLA Consortium.

Other researchers: Yelena Bagdasarova, Roberto Bonelli, Steven Clarke, Maciej Daniszewski, Coen De Vente, Samaneh Farashi, Una Greferath, Satya Gunnam, Jenna Hall, Jiru Han, Marco Herold, Alex Hewitt, Victoria E Jackson, Aaron Lee, Helena Liang, Grace Lidgerwood, Jessica Ma, Luz D Orozco, Joseph Powell, Matt Rutar, Clarisa Sánchez, Roy Schwartz, Liam W Scott, Manisha Shah, Kaylene Simpson, Scott Song, Anand Swaroop, Kirstan Vessey.

MACUSTAR consortium members: H. Agostini, I. D. Aires, L. Altay, R. Atia, F. Bandello, P. G. Basile, J. Batuca, C. Behning, M. Belmouhand, M. Berger, A. Binns, C. J. F. Boon, M. Böttger, J. E. Brazier, C. Carapezzi, J. Carlton, A. Carneiro, A. Charil, R. Coimbra, D. Cosette, M. Cozzi, D. P. Crabb, J. Cunha-Vaz, C. Dahlke, H. Dunbar, R. P. Finger, E. Fletcher, M. Gutfleisch, F. Hartgers, B. Higgins, J. Hildebrandt, E. Höck, R. Hogg, F. G. Holz, C. B. Hoyng, A. Kilani, J. Krätzschar, L. Kühlewein, M. Larsen, S. Leal, Y. T. E. Lechanteur, D.

Lu, U. F. O. Luhmann, A. Lüning, N. Manivannan, I. Marques, C. Martinho, A. Miliu, K. P. Moll, Z. Mulyukov, M. Paques, B. Parodi, M. Parravano, S. Penas, T. Peters, T. Peto, S. Priglinger, R. Ramamirtham, R. Ribeiro, D. Rowen, G. S. Rubin, J. Sahel, C. Sánchez, O. Sander, M. Saßmannshausen, M. Schmid, S. Schmitz-Valckenberg, J. Siedlecki, R. Silva, E. Souied, G. Staurengi, J. Tavares, D. J. Taylor, J. H. Terheyden, A. Tufail, P. Valmaggia, M. Varano, A. Wolf, N. Zakaria

NICOLA consortium members: R. Hogg, A. R. Hunter, F. Kee, B. McGuinness, J. McKnight, A. Scott, J. Woodside, I. Young.

Group-specific Acknowledgements:

We are grateful to all the participants of the NICOLA Study, and the whole NICOLA team, which includes nursing staff, research scientists, clerical staff, computer and laboratory technicians, managers and receptionists.

We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health and Care Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Supplementary Tables

Supplementary Table S1. RPD phenotyping protocol for each cohort.

Cohort	RPD definition				
	Present (+)	Absent (-)	Unknown	Questionable	Device
ALIENOR	≥5 RPD lesions on OCT ± confirmed on en face imaging (1)	0-4 RPD lesions on OCT	Excluded	Excluded	Heidelberg Spectralis
AREDS2_OCT	≥5 RPD lesions on OCT	0-4 RPD lesions on OCT	Excluded	Excluded	Bioptigen
CERA	≥5 RPD lesions on OCT confirmed on en face imaging (1)	0-4 RPD lesions on OCT	Excluded	Excluded	Heidelberg Spectralis
Duke_FEATURE	≥5 RPD lesions on OCT (1)	0-4 RPD lesions on OCT	Excluded	Excluded	Heidelberg Spectralis
EUGENDA	≥5 RPD lesions on OCT confirmed on NIR imaging (1) (5)	0-4 RPD lesions on OCT	Excluded	Excluded	Heidelberg Spectralis
Genentech	En face with FAF / IR (≥1 RPD lesions on OCT only for RPD Questionable)	0 RPD lesions on OCT	Excluded	Excluded	FAF / IR (Cirrus OCT for RPD Questionable)
Hadassah	≥5 RPD lesions on OCT (7)	0 RPD lesions on OCT	In with RPD-	In with RPD-	Heidelberg Spectralis
LEI	≥10 RPD lesions on OCT confirmed on NIR imaging (1)	0-9 RPD lesions on OCT	Excluded	Excluded	Heidelberg Spectralis
MACUSTAR	≥5 RPD lesions on OCT ± confirmed on NIR imaging (1)	0-4 RPD lesions on OCT	In with RPD-	Excluded	Heidelberg Spectralis
Montrachet	≥1 RPD lesions on OCT confirmed on NIR imaging (11)	0 RPD lesions on OCT	Excluded	Excluded	Heidelberg Spectralis
NEI_Research	≥1 RPD lesions on OCT confirmed by en face imaging (12)	0 RPD lesions on OCT	Excluded	Excluded	Heidelberg Spectralis
NIHR_Bioresource	≥5 RPD lesions on OCT (1)	0-4 RPD lesions on OCT	Excluded	Excluded	Topcon 3D 2000
NICOLA	≥1 RPD lesions on OCT (14)	0 RPD lesions on OCT	Excluded	Excluded	Heidelberg Spectralis
UBonn	≥5 RPD lesions on OCT ± confirmed on NIR imaging (1)	0-4 RPD lesions on OCT	In with RPD-	Excluded	Heidelberg Spectralis

Supplementary Table S2. Genotyping data, and quality control of SNPs prior to imputation for each cohort.

Cohort	Genotype data type available	Sample exclusion missing Rate cut-off	Related samples exclusion	Variant exclusion missing rate cut-off	Hardy-Weinberg equilibrium (HWE) outliers: cut-off	Sample heterozygosity outliers: cut-off	Tools used to calculate PCs/ relatedness
ALIENOR	Summary Statistics	> 95%	excluded (Pi_hat>0.1875)	> 98%	p<10 ⁻⁶	mean.het ₃ *sd	EIGENSTRAT/PLINK
AREDS2_OCT	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING
CERA	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING
Duke_FEATURE	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING
EUGENDA	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING
Genentech	Summary Statistics	> 98%	excluded (ZO cutoff 0.4)	> 98%	p<10 ⁻⁶	mean.het ₆ *sd	Admixture /PLINK
Hadassah	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING
LEI	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING
MACUSTAR	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING
Montrachet	Summary Statistics	> 95%	excluded (Pi_hat>0.1875)	> 98%	p<10 ⁻⁶	mean.het ₃ *sd	EIGENSTRAT/PLINK
NEI_Research	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING
NICOLA	Individualized level data*	> 95%	excluded (Pi_hat>0.1875)	> 98%	p<1e-6	> median ± 3 x IQR	PLINK/KING
NIHR Bioresource	Summary Statistics	> 98%	included	> 98%	p<5e-7	no cut-off applied	PLINK, fraposa/KING
UBonn	Individualized level data	> 98%	included	> 98%	p<5e-7	mean.het ₄ *sd	PLINK/KING

*Imputed and QC'ed data was shared with RPD consortium through access to NICOLA local server

Supplementary Table S3. Overview of the demographic and clinical characteristics across study cohorts with available individual-level data.

Cohort	Age (years, mean)	Number of Male N (%)	RPD Status Present (among AMD patients) N (%)	Total N#
ALIENOR*	83.2	149 (43.4%)	54 (36.24%)	343
AREDS2_OCT	77.1	141 (50.7%)	127 (45.68%)	147
CERA	74.4	311 (34.4%)	317 (35.07%)	873
Duke_FEATURE	71.0	35 (34.6%)	32 (31.68%)	77
EUGENDA	72.1	1433 (41.2%)	235 (6.75%)	3361
Genentech*	63.9	2738 (49.4%)	537 (43.24%)	6246
Hadassah	80.6	304 (43.1%)	396 (56.17%)	454
LEI	74.4	126 (36.9%)	120 (35.19%)	297
MACUSTAR	71.8	219 (34.8%)	149 (23.65%)	487
Montrachet*	82.2	306 (35.8%)	125 (32.9%)	854
NEI_Research*	76.1	27 (41.5%)	13 (20.0%)	55
NICOLA	Not available	Not available	141 (28.7%)	492
NIHR Bioresource*	73.9	41 (35.6%)	62 (53.45%)	116
UBonn	75	80 (36.4%)	143 (65.0%)	204

*Cohorts with summary statistics available

#Total numbers are after phenotyping and genotyping quality control steps.

Supplementary Table S4: SNP-chip array, phasing and imputation methods/reference panel for each cohort.

Cohort	Genotyping Array	Phasing software	Imputation software	Reference panel
ALIENOR	Illumina Human 610-Quad BeadChip	Eagle v2	Minimac 2.0 [#]	HRC*
AREDS2_OCT	Whole Genome Sequencing	Eagle v2.4	Minimac 4.0 [#]	HRC*
CERA	Illumina Infinium® Global Screening Array 24	Eagle v2.4	Minimac 4.0 [#]	HRC*
Duke_FEATURE	Illumina Infinium® Global Screening Array 24	Eagle v2.4	Minimac 4.0 [#]	HRC*
EUGENDA	mixed (Illumina Infinium® Global Screening Array 24 and Infinium CoreExome-24 v1.1)	Eagle v2.4	Minimac 4.0 [#]	HRC*
Genentech	Whole Genome Sequencing (Illumina)	Eagle v2	Internal imputation pipeline	HRC*
Hadassah	Illumina Infinium® Global Screening Array 24	Eagle v2.4	Minimac 4.0 [#]	HRC*
LEI	Illumina Infinium® Global Screening Array 24	Eagle v2.4	Minimac 4.0 [#]	HRC*
MACUSTAR	Illumina Infinium® Global Screening Array 24	Eagle v2.4	Minimac 4.0 [#]	HRC*
Montrachet	Illumina Human 610-Quad BeadChip	Eagle v2	Minimac 2.0 [#]	HRC*
NEI_Research	Whole Genome Sequencing	Eagle v2.4	Minimac 4.0 [#]	HRC*
NICOLA	Infinium CoreExome-24 v1.1	Eagle v2.3	Minimac 3.0 [#]	HRC*
NIHR-Bioresource	UK Biobank Axiom Array, version 2.1	Eagle v2	Minimac 4.0 [#]	HRC*
UBonn	Illumina Infinium® Global Screening Array 24	Eagle v2.4	Minimac 4.0 [#]	HRC*

* Haplotype Reference Consortium release 1 (HRC r1.1 2016)

Michigan imputation server

Supplementary Table S5: Number of SNPs included in the meta-analysis after post-imputation QC, lambda, and effective number of samples for each cohort.

Cohort	Number of SNPs used in met analysis	Lambda	Neff
ALIENOR	7,324,173	0.94	68.9
AREDS2_OCT	8,045,889	1.09	73.1
CERA	7,459,799	1.01	334.2
Duke_FEATURE	7,520,155	1.19	35.6
EUGENDA	7,067,373	1.01	383.4
Genentech	7,863,286	1.01	609.6
Hadassah	7,672,138	1.04	202.4
LEI	7,521,934	1.03	131.1
MACUSTAR	7,547,158	1.04	159.6
Montrachet	8,369,653	0.93	166.9
NEI_Research	7,438,926	1.31	18.8
NICOLA	7,701,609	1.01	166.7
NIHR Bioresource	7,542,723	1.11	57.7
UBonn	6,984,307	1.1	35.6

Supplementary Table S6. Overall AMD GWAS. The lead SNP risk loci at genome-wide significant cut-off ($P < 5e-8$).

Genomic Locus	Lead SNP	Chr:pos	p	Beta	Risk allele (MAF)	Identified in previous AMD GWAS
chr 1	rs7514261	1:196700914:A:G	$3.5e^{-42}$	-0.82	A (0.28)	(16,17)
chr 10	rs11200632	10:124211536:A:G	$1.98e^{-33}$	0.66	G (0.36)	(16,17)
chr 6	rs7772063	6:31906334:T:A	$4.4e^{-12}$	-0.87	A (0.06)	(16,17)

Supplementary Table S7. Genome-wide and suggestive significant signals in RPD GWAS. One genome-wide significant locus was identified as associated with RPD in the meta-analysis GWAS. Pos = genomic location, chr= chromosome.

rsID	chr	pos	beta	Overall MAF of the risk allele	MAF case: MAF ctrl *	Risk allele	p-value
rs11200638	10	124220544	0.25	0.6	0.5:0.34	A	3.7e-15
rs76361335	18	28422097	0.5	0.01	0.02:0.01	A	3.9e-07

* The average of MAF across cohorts in cases and controls.

Supplementary Table S8: Number of samples in GWAS1 (autosomal and chr X), GWAS2, GWAS3 and non-additive GWAS for each cohort.

Cohort	GWAS1 (chr 1-22)		GWAS1 (chr X)		Conditional GWAS (chr 1-22)		GWAS2		GWAS3		Non-additive GWAS (chr 1-22)	
	AMD/RPD+	AMD/RPD-	AMD/RPD+	AMD/RPD-	AMD/RPD+	AMD/RPD-	AMD/RPD+	no AMD	AMD/RPD-	no AMD	AMD/RPD+	AMD/RPD-
ALIENOR	50	78	NA	NA	50	78	50	215	78	215	50	78
AREDS2_OCT	68	79	NA	NA	68	79	NA	NA	NA	NA	68	79
CERA	306	377	306	377	306	377	306	190	377	190	306	377
Duke_FEATURE	30	47	30	47	30	47	NA	NA	NA	NA	30	47
EUGENDA	223	1512	223	1512	223	1512	223	1626	1512	1626	223	1512
Genentech	537	705	537	705	537	705	537	5004	705	5004	537	705
Hadassah	259	174	259	174	259	174	259	21	174	21	259	174
LEI	107	153	107	153	107	153	107	37	153	37	107	153
MACUSTAR	109	332	109	332	109	332	109	46	332	46	109	332
Montrachet	125	255	NA	NA	125	255	125	474	255	474	125	255
NEI_Research	12	43	NA	NA	12	43	NA	NA	NA	NA	12	43
NICOLA	141	351	NA	NA	141	351	NA	NA	NA	NA	141	351
NIHR Bioresource	62	54	NA	NA	62	54	NA	NA	NA	NA	62	54
UBonn	136	21	136	21	136	21	136	47	21	47	136	21
Total	2165	4181	1707	3321	2165	4181	1852	7660	3607	7660	2165	4181

Supplementary Table S9. GWAS2 and GWAS3 results compared to previous AMD-GWAS studies.

Genomic Locus	Tagging SNP_GWAS2	Tagging SNP_GWAS3	p_GWAS2	p_GWAS3	Identified in previous AMD GWAS studies
chr 1	1:196679455:A:C	1:196660995:A:T	7.03E-69	1.95E-72	(16,17)
chr 10	10:124215315:G:T	10:124202126:A:T	6.11E-85	1.24E-42	(16,17)
chr 10	10:30470900:A:G	NA	4.67E-09	Not GW-significant	(16,17)
chr 10	10:31036512:C:T	NA	2.61E-08	Not GW-significant	(16,17)
chr 19	19:6718387:C:G	19:6718387:C:G	2.64E-13	5.52E-11	(16,17)
chr 4	NA	4:177124573:A:T	Not GW-significant	3.30E-08	-
chr 6	6:70629849:C:T	NA	1.82E-08	Not GW-significant	-
chr 7	7:28155583:C:T	NA	1.75E-08	Not GW-significant	-
chr 9	9:136534858:A:G	NA	1.98E-09	Not GW-significant	-
chr 11	11:10407656:G:T	NA	Not GW-significant	2.20E-08	-
chr 12	12:78601978:A:G	NA	3.40E-08	Not GW-significant	-
chr 15	15:68884204:A:G	NA	4.55E-09	Not GW-significant	-
chr 17	17:49383760:A:C	NA	1.80E-08	Not GW-significant	-
chr 20	20:45480514:C:T	NA	4.71E-08	Not GW-significant	(16,17)
chr 21	21:19483180:A:T	NA	3.50E-08	Not GW-significant	-

* Only genome-wide significant results are displayed.

Supplementary Table S10. The union of RPD risk loci at suggestive significant cut-off ($P < 1e-6$) in additive and non-additive (recessive and dominant) models.

MarkerName	P (dominant model)	BETA (dominant model)	P (recessive model)	BETA (recessive model)	P (additive model)	BETA (additive model)	Gene
10:124227624:C:T	1.99e-07	-0.23	8.99e-07	-0.21	4.85e-15	-0.245	HTRA1/ARMS2/ BX842242.1
10:124229203:C:T	3.57e-07	-0.23	NaN	NaN	1.60e-14	-0.24	HTRA1/ARMS2/ BX842242.1
6:125474791:T:G	Not significant	-	3.8e-07	-0.22	-	Not significant	TPD52L1/ HDCC2
7:22333231:A:G	Not significant	-	7.8e-07	0.22	-	Not significant	RAPGEF5
7:22334012:G:C	Not significant	-	5.9e-07	-0.22	-	Not significant	RAPGEF5

Supplementary Table S11. The Wald test results compare the odds ratios between the different cohorts.

Comparison	Wald Statistic	P-value
AMD/RPD++ vs AMD/RPD+	7.451	0.006339
AMD/RPD++ vs AMD/RPD-	19.753	0.000009
AMD/RPD+ vs AMD/RPD-	19.006	0.000013

Supplementary Table S12: Haplotype blocks identified within RPD risk region.

Haplotype block	CHR	BP1	BP2	KB	NSNPS
H0	10	124199141	124206780	7.64	16
H1	10	124208466	124208520	0.055	2
H2	10	124216372	124223818	7.447	36
H3	10	124225297	124225685	0.389	3
H4	10	124226154	124226983	0.83	8

Supplementary Table S13. eQTL results for RPD-risk region, Genentech data.

Gene	tissue	estimate	std.error	statistic	p.value	fd
BX842242.1	Retina, non-Macula	0.210685	0.069966	3.011259	0.003135	0.037625
HTRA1	Retina, Macula	-0.15167	0.051023	-2.97262	0.003597	0.039569
BX842242.1	Retina, Macula	0.230705	0.078471	2.94001	0.003968	0.039682
BX842242.1	RPE, non-Macula	0.345614	0.11852	2.916081	0.00422	0.039682

Supplementary Table S14. eQTL results for RPD-risk region, NEI data.

Gene	tissue	estimate	std.error	statistic	p.value
BX842242.1	RPE	0.319	0.0455	7.02	9.76E-12
HTRA1	RPE	-0.0835	0.0268	-3.11	1.99E-03
PLEKHA1	RPE	0.00745	0.0288	0.259	7.96E-01

Supplementary Table S15: Ethics committees and approval number for each clinical cohort.

Cohort Name	Ethics Committee / Institutional Review Board	Decision (Approved/Waived)	Ethics Number	Clinical Site / Principal Investigator
ALIENOR	Ethical Committee of Bordeaux (Comité de Protection des Personnes Sud-Ouest et Outre-Mer III)	Approved	2006/10	Not applicable
AREDS2_OCT	National Institute of Health Institutional Review Board	Approved	08-EI-0043	Not applicable
CERA	The Royal Victorian Eye and Ear Hospital Human Research Ethics Committee	Approved	20/1459H; 95/283H/15; 11/1031H (Project AMD, AMDRFS, iPSC)	Not applicable
Duke_FEATURE	Duke University Institutional Review Board	Approved	#00036248; #00107399	Not applicable
EUGENDA	Ethics committees of University Hospital Cologne, Germany and Nijmegen, Netherlands	Approved	07-030	Not applicable
Genentech	Nova Scotia Health Authority Research Ethics Board, Halifax Canada	Approved	No number; Chroma	Alan Cruess
Genentech	Belberry Human Research Ethics Committee, Eastwood Australia	Approved	No number; Chroma	Alan Luckie; Jennifer Arnold; Paul Mitchell
Genentech	Quorum, Seattle USA	Approved	No number; Chroma	Alan Ruby; Ali Tabassian, Allen Thach; Brad Baker; Brandon Busbee; Brian Berger; Carmelina Gordon; Clement Chan; Dante Pieramici; Darma Ie; David Boyer; David Callanan; David Eichenbaum; Dennis Marcus; Dilsher Dhoot; George Novalis; Glenn Stoller; Gregg Kokame; Gregory A Fox; H-Logan Brooks-Jr; Howard Fine; Ivan Suner; James Combs; Jaed Nielsen; Jeffrey Heier; Jeffrey Morre; Jeffrey Zheutlin; Karl Olsen; Laurent Lalonde; Lawrence Singerman; Mark Michels; Matthew Wood; Michael Ober; Miguel Busquets; Patrick Higgins; Paul Lee; Paul Raskauskas; Philip Ferrone; Pravin Dugel; Raj Maturi; Randy Katz; Ricky Isernhagen; Robert Hampton, Robert Johnson; Robert Kwun, Robert Stoltz; Robert Wirthlin; Robert Wong; Ryan Tarantola; Sam Mansour; Sanford Chen; Seong Lee; Soraya Rofagha; Stuart Burgess; Sunil Guta; Sunil Patel; Todd Schneiderman; Veeral Sheth; Victor Gonzalez; Vrinda Hershberger
Genentech	Comite de Etica en Investigacion Clinica (CEIC), Buenos Aires Argentina	Approved	No number; Chroma	Alberto Zambrano; Carlos Zeolite; Federico Furno Sola; Patricio Schlottmann
Genentech	Medical Research Council, Ethics Committee for Clinical Pharmacology, Budapest Hungary	Approved	No number; Chroma	Andras Seres; Attila Vajas; Balazs Varsanyi
Genentech	Wester International Review Board, Puyallup USA	Approved	No number; Chroma	Andre Witkin; Barbara Blodi; Richard Feist
Genentech	Vanderbilt University Institutional Review Board, Nashville USA	Approved	No number; Chroma	Anita Agarwal

Genentech	Comites de protection des personnes (CPP) Ile de France V, Paris France	Approved	No number; Chroma	Bahram Bodaghi; Catherine Francais; Eric Souied; Ramin Tadayoni; Salomon Yves Cohen
Genentech	National Research Ethics Service (NRES) Committee North East, Newcastle & North Tyneside 1, Jarrow UK	Approved	No number; Chroma	Baljean Dhillon; Christopher Brand; Sajjad Mohmood, Sanjiv Banerjee; Tim Jackson
Genentech	Ethics Committee of the Hospital Zilina, Zilina Slovakia	Approved	No number; Chroma	Blandina Lipkova
Genentech	Komisja Bioetyczna przy Okregowej Izbie Lekarskiej w Gdansk, Gdansk Poland	Approved	No number; Chroma	Bozena Romanowska-Dixon; Dorota Raczynska; Slawomir Teper
Genentech	De Videnskabetiske Komiteer for Region Hovedstade, Hillrod Denmark	Approved	No number; Chroma	Caroline Laugesen
Genentech	Ethik-Kommission der Medizinischen Hochschule Hannover, Hannover Germany	Approved	No number; Chroma	Carsten Framme
Genentech	Ethik-Kommission der Arztekammer Westfalen-Lippe, Munster Germany	Approved	No number; Chroma	Daniel Pauleikhoff; Nicole Eter
Genentech	Comite de Etica en Investigacion de Mexico Centre for Clinical Research SA de CV, Distrito Federal Mexico, Mexico	Approved	No number; Chroma	David Lozano Rechy
Genentech	University of British Columbia Clinical Research Ethics Board, Vancouver Canada	Approved	No number; Chroma	David Maberley
Genentech	Ce Indip. Presso la fond. Ptv Policl. Tor Vergata, Roma Italy	Approved	No number; Chroma	Federico Ricci
Genentech	Comitato Di Bioetica Della ASL Di Sassari, Sassari Italy	Approved	No number; Chroma	Francesco Boscia
Genentech	Comitato Etico Milano Area B, Milano Italy	Approved	No number; Chroma	Francesco Viola
Genentech	Ethikkommission an der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn, Bonn Germany	Approved	No number; Chroma	Frank Holz
Genentech	Medisch Ethische Toetsingscommissie Amsterdam (METC AMC), Amsterdam The Netherlands	Approved	No number; Chroma	G. Dijkman
Genentech	Chesapeake Research Review Institutional Review Board, Columbia USA	Approved	No number; Chroma	Ghassan Ghorayeb
Genentech	Comite de Bioetica de la Clinica Anglo Americana, Lima Peru	Approved	No number; Chroma	Guillermo Reategui
Genentech	Eticka komisia Nomonia Sveteho Michala, Bratislava Slovakia	Approved	No number; Chroma	Hedviga Mikova
Genentech	Comite Etico de Investigacion Clinica de la Comunidad Autonoma del Pais Vasco (CEIC-E), Vitoria Spain	Approved	No number; Chroma	Javier Araiz
Genentech	Comite Etico de Investigacion Clinica, Barcelona Spain	Approved	No number; Chroma	Javier Araiz; Javier Montero; Jordi Mones; Jorge Mataix; Laura Sararols; Luis Arias

Genentech	Lahey Clinic Institutional Review Board, Burlington, USA	Approved	No number; Chroma	Jeffrey Chang
Genentech	Human Subjects Research Office, Miami USA	Approved	No number; Chroma	Jorge Fortun
Genentech	Universiteit Gent, Commissie voor Medische Ethiek, Gent Belgium	Approved	No number; Chroma	Julie De Zaeytijd
Genentech	Ethikkommission an der Medizinischen Fakultät Universität zu Köln, Germany	Approved	No number; Chroma	Lebriz Altay
Genentech	Comite de Etica en Investigacion Clinica (CEIC) Hospital de Bellvitge, Barcelona Spain	Approved	No number; Chroma	Luis Arias
Genentech	Northwestern University Office for the Protection of Research Subjects, Chicago USA	Approved	No number; Chroma	Manjot Gill
Genentech	Eticka Komisia pri Fakultna Nemocnica Trencin, Trencin Slovakia	Approved	No number; Chroma	Marek Kacerik
Genentech	Comitato Etico Centrale Sezione - Bietti Istituti Fisioterapici Ospitalieri (IFO), Roma Italy	Approved	No number; Chroma	Maria Cristina Parravano
Genentech	Sydney Local Health District Ethics Review Committee RPAH Zone), Newtown Australia	Approved	No number; Chroma	Mark Gillies
Genentech	Ethik-Kommission der Universität Göttingen, Göttingen Germany	Approved	No number; Chroma	Nicolas Feltgen
Genentech	Ethikkommission des AKH Linz, Linz Austria	Approved	No number; Chroma	Nicole Schnelzer
Genentech	Sunnybrook Science Health Centre, Toronto Canada	Approved	No number; Chroma	Peter Kertes
Genentech	University of Texas Southwestern, Dallas USA	Approved	No number; Chroma	Rafael Ufret-Vincenty
Genentech	Wake Forest University Health Sciences Institutional Review Board, Winston-Salem USA	Approved	No number; Chroma	Rajiv Shah
Genentech	Academisch Medisch Centrum, Amsterdam Netherlands	Approved	No number; Chroma	Reinier Schlingemann
Genentech	University of California San Francisco Committee on Human Research, San Francisco USA	Approved	No number; Chroma	Robert Bhisitkul
Genentech	New York Eye & Ear Infirmary, Icahn School of Medicine at Mount Sinai Institutional Review Board, New York USA	Approved	No number; Chroma	Ronald Gentile
Genentech	EK Lubeck Institutional Review Board, Lubeck Germany	Approved	No number; Chroma	Salvatore Grisanti
Genentech	St Michael's Hospital Institutional Review Board, Toronto Canada	Approved	No number; Chroma	Shelley Boyd
Genentech	Kantonale Ethikkommission Zurich, Zurich Switzerland	Approved	No number; Chroma	Stephan Michels

Genentech	University of California Los Angeles Office of the Human Research Protection Program, Los Angeles USA	Approved	No number; Chroma	Stephan Schwartz
Genentech	The Cleveland Clinic Institutional Review Board, Cleveland USA	Approved	No number; Chroma	Sumit Sharma
Genentech	Comite de Etica en Investigacion de la Asociacion para Evitar la Ceguera en Mexico IAP, Ciudad de Mexico, Mexico	Approved	No number; Spectri	Virgilio Morales Canton
Genentech	Quorum, Seattle USA	Approved	No number; Spectri	Alan Gordon; Alexamder Eaton; Allen Ho; Andrew Antosyzk; Brian Connolly; Cameron Javid; Carl Baker; Charles C Wykoff; Christine R Gonzales; Daniel Miller; Dante Pieramici; David Eichenbaum; David Saperstein; David M Brown; Deeba Husain; Eric Suan; H Logan Brooks Jr; Jared Nielsen; Joel Pearlman, Jonathan Williams; Jorge Calzada William Brides Jr; K Baily Freund; Larry Helperin; Leonard Feiner; Lloyd Clark; Mark Johnson, Mark Wieland; Mimi Liu; Nancy Holekamp; Nauman Chaudhry; Nokolas London; Paul Wishaar; Peter Pavan; Prema Abaham; Raymond Sjaarda; Richard Breazeale; Richard Dreyer; Robert C Wang; Scott Foxman; Sean Adrean; Subhransu K Ray; Sunil Patel; Virgil Alfaro; William Durant;
Genentech	Comite de Etica en Investigacion Clinica (CEIC) de Navarra, Dapartamento de Salud Pabellon de Docencia, Pamplona Spain	Approved	No number; Spectri	Alfredo Garcia-Layana; Francisco Gomez Ulla; Jose Manuel Ortiz; Marta Figueroa; Rafael Navarro; Ramon Torres; Roberto Gellego-Pinazo Imaz
Genentech	Regionala Etikprovningssamndem I Stockholm Karolinska Institute, Stockholm Sweden	Approved	No number; Spectri	Anders Kvanta
Genentech	Ethick-Kommission der Universitat Regensburg, Germany	Approved	No number; Spectri	Andreea Gamulescu
Genentech	Eticka komisia UN Bratislava, Bratislava Slovakia	Approved	No number; Spectri	Andrej Cernak
Genentech	National Research Ethics Service (NRES) Committee South Central-Berkshire, Bristol UK	Approved	No number; Spectri	Andrew Lotery; Andrew Browning; Clare Bailey; Faruque Ghanchi; Ian Pearce; Michel Williams; Niro Narendran; Quresh Mohamed; Richard Gale; Simona Esposti
Genentech	Samara State Medical University, Samara Russian Federation	Approved	No number; Spectri	Andrey Zolotarev
Genentech	Comissao de Etica para Investigacao Clinica, Lisboa Portugal	Approved	No number; Spectri	Angela Carneiro
Genentech	Belberry Human Research Ethics Committee, Eastwood Australia	Approved	No number; Spectri	Anthony Kwan; Devinder Chauhan; Fred Chen; Jagjit Gilhotra
Genentech	Ethikkommission der Medizinischen Fakultat, Munchen Germany	Approved	No number; Spectri	Armin Wolf
Genentech	Comite de Etica en Investigacion Clinica (CEIC), Buenos Aires Argentina	Approved	No number; Spectri	Arturo Alezzandrini; Mauricio Martinez Cartier

Genentech	Medical Research Council, Ethics Committee for Clinical Pharmacology, Budapest Hungary	Approved	No number; Spectri	Balazs Varsanyi; Jonos Nemeth; Peter Vamosi
Genentech	Hacettepe University Medical Faculty Clinical Research Ethics Committee, Ankara Turkey	Approved	No number; Spectri	Bora Eldem; Gursel Yilmaz; Jale Menten; Nur Kir; Osman Saatci
Genentech	Wills Eye Hospital Institutional Review Board, Philadelphia USA	Approved	No number; Spectri	Carl Regillo
Genentech	Medisch Ethische Toetsingscommissie Amsterdam (METC AMC), Amsterdam The Netherlands	Approved	No number; Spectri	Carel Hoyng
Genentech	Comite Etica para la Investigacion Universidad de San Martin de Porres, Lima Peru	Approved	No number; Spectri	Carlos Fernandez; Silvio Lujan
Genentech	Comites de protection des personnes (CPP) Sud Ouest Et Outre Mer III, Bordeaux France	Approved	No number; Spectri	Catherine Creuzot Garcher; Francois Devin; Jean Francois Korobelnik; Laurent Kodjikian; Michel Weber; Saddek Mohand Said
Genentech	Citta della salute e della scienza di Torino, Comitato Etico, Torino Italy	Approved	No number; Spectri	Chiara Eandi
Genentech	Ethikkommission Technische Universitat Munchen, Munchen Germany	Approved	No number; Spectri	Chris P Lohmann
Genentech	Oregon Health and Science University Institutional Review Board, Portland USA	Christina Flaxel	No number; Spectri	Christina Flaxel
Genentech	University of California Los Angeles Office of the Human Research Protection Program, Los Angeles USA	Approved	No number; Spectri	David Sarraf
Genentech	University of Nebraska Medical Center Institutional Review Board, Omaha USA	Approved	No number; Spectri	Diana Do
Genentech	Duke University Health System Institutional Review Board, Durham USA	Approved	No number; Spectri	Eleanora Lad
Genentech	SAHI Republic Clinical Ophthalmological Hospital of Ministry of Health of Tatarstan Republic, Kazan Russian Federation	Approved	No number; Spectri	Elmira Abdulaeva
Genentech	Komisja Bioetyczna przy Okregowej Izbie Lekarskiej, Bydgoszcz Poland	Approved	No number; Spectri	Ewa Herba; Jakub Kaluzny; Jerzy Nawrocki; Marta Misiuk-Hojlo
Genentech	Comitato Etico Irccs Ospedale San Raffaele, Milano Italy	Approved	No number; Spectri	Francesco Bandello
Genentech	Comite Etico de Investigacion Clinica de Galicia, Subdireccion Xeral de Farmacia e Produtos Sanitar, Santiago de Compostela, A Coruna Spain	Approved	No number; Spectri	Francisco Gomez Ulla
Genentech	Wayne State University Human Investigation Committee, Detroit USA	Approved	No number; Spectri	Gary Abrams
Genentech	Ethikkommission der Medizinischen Fakultat, Heidelberg Germany	Approved	No number; Spectri	Gerd Auffarth
Genentech	Comitato Etico Area Vasta Centra, Fireze Italy	Approved	No number; Spectri	Gianni Virgili
Genentech	Comitato Etico Interaziendale Milano Area A, Milano Italy	Approved	No number; Spectri	Giovanni Staurengi

Genentech	Etik-Kommission der Albert-Ludwigs Universitat, Freiburg Germany	Approved	No number; Spectri	Hansjurgen Agostini
Genentech	Univesity of California San Diego Human Research Protections Program, La Jolla USA	Approved	No number; Spectri	Henry Ferreyra
Genentech	Comite de Etica en Investigacion Clinica (CEIC) Complejo Hospitalario de Albacete, Albacete Spain	Approved	No number; Spectri	Jose Manuel Ortiz
Genentech	Comite de Etica en Investigacion de Mexico Centre for Clinical Research SA de CV, Distrito Federal Mexico, Mexico	Approved	No number; Spectri	Juan Ramirez Estudillo
Genentech	UZ Leuven Gasthuisberg, Commissie Medische Ethiek, Leuven Belgium	Approved	No number; Spectri	Julie Jakob
Genentech	Ethikkommission Nordwest- und Zentralschweiz, Basel Switzerland	Approved	No number; Spectri	Katja Hatz
Genentech	Ethik-Kommission der Landesärztekammer Rheinland-P, Mainz Germany	Approved	No number; Spectri	Lars-Olof Hattenbach
Genentech	CHU Brugmann (Victor Horta), Comite d'Etique, Broxelles Belgium	Approved	No number; Spectri	Laurence Postelmans
Genentech	University of California Davis Institutional Review Board, Sacramento USA	Approved	No number; Spectri	Lawrence Morse
Genentech	Medical University of South Carolina Office of Research Integrity Institutional Review Board, Charleston USA	Approved	No number; Spectri	Lucian Del Priore
Genentech	Comite de Etica en Investigacion Clinica (CEIC) Hospital Universitario La Princesa, Madrid, Spain	Approved	No number; Spectri	Marta Figueroa; Ramon torres Imaz
Genentech	Comitato Etico Regione Liguria (Sezione 2), Gonova Italy	Approved	No number; Spectri	Massimo Nicolo
Genentech	Western Institutional Review Board, Puyallup USA	Approved	No number; Spectri	Matthew Ohr; Nieraj Jain; Scott Oliver
Genentech	De Videnskabetiske Komiteer for Region Hovedstade, Hillrod Denmark	Approved	No number; Spectri	Michael Larsen
Genentech	Comite Institucional de Etica en Investigacion de la Asociacion Benefica Prisma, Lima Peru	Approved	No number; Spectri	Miguel Guzman
Genentech	Comitato Etico Regionale Unico (CERU), Udine Italy	Approved	No number; Spectri	Paolo Lanzetta
Genentech	Johns Hopkins Medine Institutional Review Board, Baltimore USA	Approved	No number; Spectri	Peter Campochiaro
Genentech	University of Miami Miller School of Medicine, Human Subject Research Office, Miami USA	Approved	No number; Spectri	Philip Rosenfeld
Genentech	Instituto de Microcirugia Ocular Comite de Etica en Investigacion Clinica (CEIC), Barcelona Spain	Approved	No number; Spectri	Rafael Navarro
Genentech	Instituto Mexicano de Oftalmologia, Comite de Etica en Investigacion (CEI), Quereta Mexico	Approved	No number; Spectri	Renata Garcia Franco
Genentech	Scott and White Memorial Hospital Institutional Review Board, Temple USA	Approved	No number; Spectri	Robert Rosa

Genentech	Comite Etico de Investigacion Clinica, Hospital Universitario I Politecnico LA FE, Valencia Spain	Approved	No number; Spectri	Roverto Gellego-Pinazo
Genentech	Human Research and Ethics Committee Royal Victorian Eye and Ear Hospital, East Melbourne Australia	Approved	No number; Spectri	Robyn Guymer
Genentech	Comissao de Etica para Investigacao Clinica (CEIC), Lisboa Portugul	Approved	No number; Spectri	Rufino Silva; Sara Vaz-Pereira
Genentech	Kantonale Ethikkommission Bern KEK, Bern Switzerland	Approved	No number; Spectri	Sebastian Wolf
Genentech	Weill Cornell Medical Center Institutional Review Board	Approved	No number; Spectri	Szilard Kiss
Genentech	Standford University Research Compliance Office, Palo Alto USA	Approved	No number; Spectri	Theodore Leng
Genentech	Ethik-Kommission der Medizinischen Fakultät der Eberhard-Kars-Universität und am Uniklinikum, Tübingen Germany	Approved	No number; Spectri	Ulrich Bartz-Schmidt
Genentech	Ethikkommission der Universität Wien/AKH, Wien Austria	Approved	No number; Spectri	Ursula Schmidt-Erfurth
Genentech	FSBI Scientific Research Institute of Eye Diseases of Russia Academy of Medical Sciences, Moscow Russian Federation	Approved	No number; Spectri	Valery Erichev
Genentech	University of Virginia Institutional Review Board for Health Sciences Research, Charlottesville, USA	Approved	No number; Spectri	Yevgeniy Shildkrot
Genentech eQTL	Pharma Repository Governance Committee at Genentech (Genentech/Roche Institutional Ethical Committee)	Approved	No number	Not applicable
Hadassah	Institutional review board of the Hadassah Medical Center	Approved	#382-19	Not applicable
LEI	Sir Charles Gairdner Group Human Research Ethics Committee	Approved	2013-118 (LEAD)	Not applicable
LEI	University of Western Australia, Human Ethics Office of Research	Approved	2021/ET000151 (WARD)	Not applicable
MACUSTAR	University Hospital Bonn Ethics Committee	Approved	384/17	CS015
MACUSTAR	Paris Ouest IV Ethics Committee	Approved	04/18_2	CS003
MACUSTAR	AIBILI Ethics Committee	Approved	032/2017/AIBILI/CE	CS001
MACUSTAR	Comissão de Ética para a Saúde do CHSJ	Approved	dated 12/01/2018	CS032
MACUSTAR	London Queen Square Research Ethics Committee	Approved	18/LO/0145	CS010
MACUSTAR	Center for Sundhed Glostrup Ethics Committee	Approved	H-18000126	CS030
MACUSTAR	Comitato Etico Milano	Approved	37910/2018	CS034
MACUSTAR	Il Comitato Etico dell'Ospedale San Raffaele	Approved	dated 25/10/2018	CS067
MACUSTAR	Radboudumc Technology Center Ethics Committee	Approved	2017-3954	CS017
MACUSTAR	LUMC commissie medische ethiek	Approved	L18.055/SH/sh	CS106
Montrachet	Kremlin Bicetre and Dijon Ethics Committee	Approved	2009-A00448-49	Not applicable

NEI_Research	National Institute of Health Institutional Review Board	Approved	CR002060	Not applicable
NEI_eQTL	National Institute of Health Ethics Committee	Waived (no way to identify individuals that have donated post-mortem retina samples)	Not applicable	Not applicable
NIHR_Bioresource	South Central - Berkshire B Research Ethics Committee	Approved	19/SC/0337	Research Tissue Bank – RTB-GEN
NICOLA	School of Medicine, Dentistry and Biomedical Sciences Ethics Committee, Queen's University Belfast	Approved	23/12	Not applicable
UBonn	University Hospital Bonn Ethics Committee	Approved	045/18; 513/20	Not applicable

Supplementary Table S16: Models, tools and covariates used in association analysis for each cohort.

Cohort	Association Model	Association analysis tool	Covariates
ALIENOR	Logistic ridge regression model	REGENIE	sex, age, PC1:PC2
AREDS2_OCT	linear mixed model	rvtests	sex, age, PC1:PC5
CERA	linear mixed model	rvtests	sex, age, PC1:PC5
Duke_FEATURE	linear mixed model	rvtests	sex, age, PC1:PC5
EUGENDA	linear mixed model	rvtests	sex, age, PC1:PC5
Genentech	linear mixed model	rvtests	sex, age, PC1:PC5
Hadassah	linear mixed model	rvtests	sex, age, PC1:PC5
LEI	linear mixed model	rvtests	sex, age, PC1:PC5
MACUSTAR	linear mixed model	rvtests	sex, age, PC1:PC5
Montrachet	Logistic ridge regression model	REGENIE	sex, age, PC1:PC2
NEI_Research	linear mixed model	rvtests	sex, age, PC1:PC5
NICOLA	linear mixed model	rvtests	sex, age, PC1:PC5
NIHR-Bioresource	linear mixed model	rvtests	sex, age, PC1:PC5
UBonn	linear mixed model	rvtests	sex, age, PC1:PC5

References

1. Wu Z, Ayton LN, Luu CD, Baird PN, Guymer RH. Reticular Pseudodrusen in Intermediate Age-Related Macular Degeneration: Prevalence, Detection, Clinical, Environmental, and Genetic Associations. *Invest Ophthalmol Vis Sci*. 2016 Mar;57(3):1310–6.
2. Saunier V, Merle BMJ, Delyfer M-N, Cougnard-Grégoire A, Rougier M-B, Amouyel P, et al. Incidence of and Risk Factors Associated With Age-Related Macular Degeneration: Four-Year Follow-up From the ALIENOR Study. *JAMA Ophthalmol*. 2018 May 1;136(5):473–81.
3. Sleiman K, Veerappan M, Winter KP, McCall MN, Yiu G, Farsiu S, et al. Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration. *Ophthalmology*. 2017 Dec;124(12):1764–77.
4. Lad EM, Fang V, Tessier M, Rautanen A, Gayan J, Stinnett SS, et al. Longitudinal Evaluation of Visual Function Impairments in Early and Intermediate Age-Related Macular Degeneration Patients. *Ophthalmol Sci*. 2022 Sep;2(3):100173.
5. Zweifel SA, Imamura Y, Spaide TC, Fujiwara T, Spaide RF. Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration. *Ophthalmology*. 2010;117(9):1775–81.
6. Venhuizen FG, van Ginneken B, van Asten F, van Grinsven MJJP, Fauser S, Hoyng CB, et al. Automated Staging of Age-Related Macular Degeneration Using Optical Coherence Tomography. *Invest Ophthalmol Vis Sci*. 2017 Apr 1;58(4):2318–28.
7. Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. *Prog Retin Eye Res*. 2018 May;64:1–55.
8. Shmueli O, Yehuda R, Szeskin A, Joskowicz L, Levy J. Progression of cRORA (Complete RPE and Outer Retinal Atrophy) in Dry Age-Related Macular Degeneration Measured Using SD-OCT. *Transl Vis Sci Technol*. 2022 Jan 3;11(1):19–19.
9. Roshandel D, Thompson JA, Heath Jeffery RC, Zhang D, Lamey TM, McLaren TL, et al. Clinical Evidence for the Importance of the Wild-Type PRPF31 Allele in the Phenotypic Expression of RP11. *Genes* [Internet]. 2021 Jun 14;12(6). Available from: <http://dx.doi.org/10.3390/genes12060915>

10. Saßmannshausen M, Thiele S, Behning C, Pfau M, Schmid M, Leal S, et al. Intersession Repeatability of Structural Biomarkers in Early and Intermediate Age-Related Macular Degeneration: A MACUSTAR Study Report. *Transl Vis Sci Technol*. 2022 Mar 2;11(3):27–27.
11. Gabrielle P-H, Seydou A, Arnould L, Acar N, Devilliers H, Baudin F, et al. Subretinal Drusenoid Deposits in the Elderly in a Population-Based Study (the Montrachet Study). *Invest Ophthalmol Vis Sci*. 2019 Nov 1;60(14):4838–48.
12. Flamendorf J, Agron E, Wong WT, Thompson D, Wiley HE, Doss EL, et al. Impairments in Dark Adaptation Are Associated with Age-Related Macular Degeneration Severity and Reticular Pseudodrusen. *Ophthalmology*. 2015;122(10):2053–62.
13. Mukherjee S, De Silva T, Grisso P, Wiley H, Tiarnan DLK, Thavikulwat AT, et al. Retinal layer segmentation in optical coherence tomography (OCT) using a 3D deep-convolutional regression network for patients with age-related macular degeneration. *Biomed Opt Express*. 2022 Jun 1;13(6):3195–210.
14. Sohrab MA, Smith RT, Salehi-Had H, Sadda SR, Fawzi AA. Image registration and multimodal imaging of reticular pseudodrusen. *Invest Ophthalmol Vis Sci*. 2011 Jul 29;52(8):5743–8.
15. Quinn NB, Chakravarthy U, Muldrew KA, Hamill B, McGuinness B, Young IS, et al. Confocal infrared imaging with optical coherence tomography provides superior detection of a number of common macular lesions compared to colour fundus photography. *Ophthalmic Physiol Opt*. 2018;38(6):574–83.
16. Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nat Genet*. 2016 Feb;48(2):134–43.
17. Han X, Gharahkhani P, Mitchell P, Liew G, Hewitt AW, MacGregor S. Genome-wide meta-analysis identifies novel loci associated with age-related macular degeneration. *J Hum Genet*. 2020 Aug;65(8):657–65.